Susan Joseph
Advanced Heart Failure and Transplant Cardiology · Baltimore, MDNPI 1487860060
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Abbott accounts for 60.7% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $37,133 and has fallen 81.6% since, to $6,824 in 2025.
Across 311 payments — averaging $208.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$39K
- Ancora Heart, Inc.$8K
- Medtronic$7K
- Novartis$3K
- Impulse Dynamics (USA) Inc.$3K
- Cvrx, Inc.$2K
- plus $3K from 18 others
Across 23 payments — averaging $4999.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$87K
- AstraZeneca$21K
- Impulse Dynamics (USA) Inc.$4K
- Abbott$3K
What the payments were for
- Consulting fees$38,46359%
- Travel & lodging$12,16919%
- Food & beverage$14,11222%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 168 | $39,279 |
| Ancora Heart, Inc. | 16 | $7,872 |
| Medtronic(2 entities) | 18 | $6,990 |
| Novartis | 8 | $3,402 |
| Impulse Dynamics (USA) Inc. | 24 | $2,527 |
| Cvrx, Inc. | 16 | $1,504 |
| Abiomed | 11 | $787 |
| Amgen | 4 | $752 |
| Novo Nordisk | 7 | $375 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $235 |
| Atricure, Inc. | 2 | $156 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $134 |
| AstraZeneca | 1 | $120 |
| Pfizer | 5 | $101 |
| Neurocrine Biosciences, Inc. | 5 | $101 |
| Boehringer Ingelheim | 4 | $99 |
| ZOLL Respicardia, Inc. | 1 | $77 |
| Actelion Pharmaceuticals US, Inc. | 2 | $46 |
| Alnylam Pharmaceuticals Inc. | 2 | $44 |
| Johnson & Johnson | 2 | $36 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Heartflow, Inc. | 1 | $23 |
| AbbVie | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HeartMate 3 Left Ventricular Dev$16,068
- HeartMate 3 Left Ventricular Assist Device$7,719
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$4,468
- CardioMEMS HF System$3,705
- OPTIMIZER$3,520
- HeartMate Touch$2,450
- AccuCinch$1,728
- Barostim Neo System$1,183
- CARDIOMEMS$1,015
- HeartMate$276
- Impella$234
- Ozempic$229
- ATRICURE CRYOSURGICAL SYSTEM$121
- ATRICURE SYNERGY ABLATION SYSTEM$121
- FARXIGA$120
How this compares
Too few advanced heart failure and transplant cardiology providers in Marylandto place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carvedilol | 16 | $227 |
| Spironolactone | 13 | $147 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in Baltimore
- Sandeep JaniBaltimore$75K
- Kavita SharmaBaltimore$63K
- Gautam RamaniBaltimore$32K
- Joban VaishnavBaltimore$30K
- Luigi AdamoBaltimore$9K
- Mohammad Sadegh AsadiBaltimore$7K
- Steven HsuBaltimore$4K
- Weining XuBaltimore$2K
- Nisha GilotraBaltimore$718
- Virginia HahnBaltimore$256
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.